Effect of clenbuterol on non-endothelial nitric oxide release in rat mesenteric arteries and the involvement of beta-adrenoceptors.
1. The aim of the present study was to explore the contribution of adrenergic, sensory and nitrergic innervations to the inhibitory effects of the beta2-adrenoceptor agonist clenbuterol on responses to electrical field stimulation (EFS, 200 mA, 0.3 ms, 1-16 Hz, for 30 s, at 1 min interval) in rat mesenteric artery segments without endothelium and the possible involvement of adrenergic, sensory and nitrergic innervations. 2. Clenbuterol (1 microM) reduced EFS-induced contractile responses, and this effect was reversed by the beta-antagonist propranolol (1 microM) (contraction at 16 Hz expressed as % of 75 mM K+-induced contraction was: control, 69+/-9, clenbuterol, 31+/-6, n=13, P<0.001; control, 83+/-5, clenbuterol+propranolol 70+/-7, n=11, P>0.05). 3. In arteries preincubated with [3H]-noradrenaline (NA), clenbuterol did not modify the tritium overflow evoked by EFS (200 mA, 0.3 ms, 4 Hz, for 60 s; ratio between tritium release in the second and first stimuli was: control, 0.80+/-0.05 and clenbuterol added before second stimulus, 0.91+/-0.11, n=5, P>0.05). 4. The nitric oxide (NO) synthase inhibitors NG-monomethyl-L-arginine (L-NMMA) and NG-nitro-L-arginine methyl ester (L-NAME) (10 and 100 microM), and the guanylate cyclase inhibitor methylene blue (10 microM) increased the contractions caused by EFS (% contraction at 16 Hz, control, 81+/-7, n=26; 10 microM L-NMMA, 109+/-12, n=8, P<0.05; methylene blue, 119+/-6, n=6, P<0.05). However, these contractions were decreased by the NO synthase substrate L-arginine 10 microM (14+/-6%, n=6, P<0.001), but not modified by either the sensory neurones toxin capsaicin (0.5 microM, 75+/-6%, n=6, P>0.05) or the protein synthesis inhibitor cycloheximide (10 microM, 83+/-6%, n=8, P>0.05). None of these drugs altered the concentration-response curves to exogenous NA (n=7). 5. Pretreatment with capsaicin or cycloheximide did not modify the reduction of the EFS-evoked contraction provoked by clenbuterol. However the presence of L-NMMA (or L-NAME) or methylene blue did decrease the effect of clenbuterol (% contraction at 16 Hz, clenbuterol, 31+/-6, n=13; clenbuterol+10 microM L-NMMA, 93+/-11, n=8, P<0.05; clenbuterol+methylene blue, 90+/-7, n=6, P<0.05). 6. These results suggest that the reduction caused by clenbuterol in the contraction induced by EFS in rat mesenteric arteries seems to be mediated by NO release, through the activation of beta2-adrenoceptors probably present on nitrergic nerves.
Marín
J
J
Departamento de Fisiología, Facultad de Medicina, Universidad Autónoma, Madrid, Spain.
Balfagón
G
G
D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000818:Animals; D002976:Clenbuterol / Q000494:pharmacology*; D004558:Electric Stimulation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006162:Guanylate Cyclase / Q000037:antagonists & inhibitors; D066298:In Vitro Techniques; D008297:Male; D008564:Membrane Potentials / Q000502:physiology; D008638:Mesenteric Arteries / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology; D009119:Muscle Contraction / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D009569:Nitric Oxide / Q000378:metabolism*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D052247:Nitric Oxide Synthase Type II; D009638:Norepinephrine / Q000378:metabolism; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D011943:Receptors, Adrenergic, beta / Q000187:drug effects / Q000502:physiology*
D000318:Adrenergic beta-Agonists; D004791:Enzyme Inhibitors; D011500:Protein Synthesis Inhibitors; D011943:Receptors, Adrenergic, beta; D009569:Nitric Oxide; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; C496318:Nos2 protein, rat; D006162:Guanylate Cyclase; D009638:Norepinephrine; D002976:Clenbuterol